The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
AlloVir, Inc(NASDAQ:ALVR) 
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is Viralym-M, an allogeneic, off-the-shelf VST...
Website: http://www.allovir.com
Founded: 2013
Full Time Employees: 32
CEO: David L. Hallal
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends
AlloVir Days Payable Outstanding ttm (DPO)
AlloVir Days Inventory Outstanding ttm (DIO)
AlloVir Op Cashflow Per Share ttm
AlloVir Free Cashflow Per Share ttm
AlloVir Cash Per Share ttm
AlloVir (GAAP) P/E ratio ttm
AlloVir P/B ratio ttm
No extra charts and metrics for this ticker.